Rachael Hough

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 480 citations · Full text

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 301 citations · Full text

Hematological Malignancy, Post-remission Therapy, Young People +13

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Shaun Cordoba, Shimobi Onuoha, Simon Thomas et al. · Nature Medicine · 2021 · 260 citations · Full text

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003

David O’Connor, Jessica Bate, Rachel Wade et al. · Blood · 2014 · 244 citations

Outcome for children and young people with <scp>E</scp>arly <scp>T</scp>‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, <scp>UKALL</scp> 2003

Katharine Patrick, Rachel Wade, Nick Goulden et al. · British Journal of Haematology · 2014 · 229 citations